Periprocedural Complications and Long-Term Outcome After Alcohol Septal Ablation Versus Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy A Single-Center Experience by Steggerda, Robbert C. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 1 1 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N CO L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 4 . 0 5 . 0 2 3Periprocedural Complications
and Long-Term Outcome
After Alcohol Septal Ablation
Versus Surgical Myectomy in
Hypertrophic Obstructive Cardiomyopathy
A Single-Center ExperienceRobbert C. Steggerda, MD,* Kevin Damman, MD, PHD,y Jippe C. Balt, MD, PHD,z Max Liebregts, MD,z
Jurriën M. ten Berg, MD, PHD,z Maarten P. van den Berg, MD, PHDyJACC: CARDIOVASCULAR INTERVENTIONS CMEThis article has been selected as this issue’s CME activity, available online
at http://interventions.onlinejacc.org/ by selecting the CME tab on the
top navigation bar.
Accreditation and Designation Statement
The American College of Cardiology Foundation (ACCF) is accredited by
the Accreditation Council for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
The ACCF designates this Journal-based CME activity for a maximum of 1
AMA PRA Category 1 Credit(s). Physicians should only claim credit
commensurate with the extent of their participation in the activity.
Method of Participation and Receipt of CME Certiﬁcate
To obtain credit for this CME activity, you must:
1. Be an ACC member or JACC: Cardiovascular Interventions subscriber.
2. Carefully read the CME-designated article available online and in this
issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3 questions
provided must be answered correctly to obtain CME credit.From the *Department of Cardiology, Martini Hospital, Groningen, the Net
Groningen, University Medical Center Groningen, Groningen, the Netherlan
Hospital, Nieuwegein, the Netherlands. The authors have reported that they
paper to disclose.
Manuscript received January 13, 2014; revised manuscript received April 21,4. Complete a brief evaluation.
5. Claim your CME credit and receive your certiﬁcate electronically
by following the instructions given at the conclusion of the
activity.
CME Objective for This Article: At the completion of this article, the
learner should be able to: 1) describe the alcohol septal ablation proce-
dure and its potential complications; and 2) describe the myectomy
procedure and its potential complications.
CME Editor Disclosure: JACC: Cardiovascular Interventions CME Editor
Olivia Hung, MD, PhD, has received research grant support from NIH T32,
Gilead Sciences. and Medtronic Inc.
Author Disclosures: The authors have reported that they have no
relationships relevant to the contents of this paper to disclose.
CME Term of Approval
Issue Date: November 2014
Expiration Date: October 31, 2015herlands; yDepartment of Cardiology, University of
ds; and the zDepartment of Cardiology, St. Antonius
have no relationships relevant to the contents of this
2014, accepted May 8, 2014.
Steggerda et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 1 1 , 2 0 1 4
Complications and Outcome After ASA and Myectomy N O V E M B E R 2 0 1 4 : 1 2 2 7 – 3 4
1228Periprocedural Complications and Long-Term
Outcome After Alcohol Septal Ablation
Versus Surgical Myectomy in Hypertrophic
Obstructive CardiomyopathyA Single-Center ExperienceABSTRACTOBJECTIVES This study compared alcohol septal ablation (ASA) and surgical myectomy for periprocedural complica-
tions and long-term clinical outcome in patients with symptomatic hypertrophic obstructive cardiomyopathy.
BACKGROUND Debate remains whether ASA is equally effective and safe compared with myectomy.
METHODS All procedures performed between 1981 and 2010 were evaluated for periprocedural complications and
long-term clinical outcome. The primary endpoint was all-cause mortality; secondary endpoints consisted of annual
cardiac mortality, New York Heart Association functional class, rehospitalization for heart failure, reintervention,
cerebrovascular accident, and myocardial infarction.
RESULTS A total of 161 patients after ASA and 102 patients after myectomy were compared during a maximal follow-up
period of 11 years. The periprocedural (30-day) complication frequency after ASA was lower compared with myectomy
(14% vs. 27%, p ¼ 0.006), and median duration of in-hospital stay was shorter (5 days [interquartle range (IQR): 4 to 6
days] vs. 9 days [IQR: 6 to 12 days], p < 0.001). After ASA, provoked gradients were higher compared with myectomy (19
[IQR: 10 to 42] vs. 10 [IQR: 7 to 13], p < 0.001). After multivariate analysis, age (per 5 years) (hazard ratio: 1.34 [95%
conﬁdence interval: 1.08 to 1.65], p ¼ 0.007) was the only independent predictor for all-cause mortality. Annual cardiac
mortality after ASA and myectomy was comparable (0.7% vs. 1.4%, p ¼ 0.15). During follow-up, no signiﬁcant differ-
ences were found in symptomatic status, rehospitalization for heart failure, reintervention, cerebrovascular accident, or
myocardial infarction between both groups.
CONCLUSIONS Survival and clinical outcome were good and comparable after ASA and myectomy. More periproce-
dural complications and longer duration of hospital stay after myectomy were offset by higher gradients after ASA.
(J Am Coll Cardiol Intv 2014;7:1227–34) © 2014 by the American College of Cardiology Foundation.SEE PAGE 1235O bstruction of ﬂow in the left ventricularoutﬂow tract (LVOT) is found in w70%of patients with hypertrophic cardiomyo-
pathy, referred to as hypertrophic obstructive car-
diomyopathy (1). Although medical treatment can
provide relief of symptoms, a sizable subset of pa-
tients with hypertrophic obstructive cardiomyopathy
remains symptomatic, and in these subjects, invasive
treatment (i.e., septum reduction) is an established
treatment option (2,3). Both alcohol septal ablation
(ASA) and surgical myectomy have proved to be effec-
tive methods for relief of symptoms (4–6). In recent
studies, ASA is associated with excellent survival,
comparable to survival in an age- and sex-matched
population (7,8). Because ASA is also a less invasive
treatment than myectomy, it may thus be a preferredtreatment. On the other hand, previous studies have
also reported a greater need for pacemaker implanta-
tion and a higher rate of reinterventions after ASA
compared with myectomy (3,4), and in a single-
center study, a warning was given that ASA may in
fact increase cardiac mortality (9). We report our expe-
rience in a comprehensive study of both procedures
including periprocedural complications, survival, car-
diac survival, long-term symptomatic status, and clin-
ical outcome.METHODS
STUDY DESIGN AND PATIENT POPULATION.
All patients who underwent either ASA or a surgical
AB BR E V I A T I O N S
AND ACRONYM S
ASA = alcohol septal ablation
CABG = coronary artery bypass
grafting
CVA = cerebrovascular
accident
ICD = implantable
cardioverter-deﬁbrillator
LVOT = left ventricular
outﬂow tract
NYHA = New York Heart
Association
SCD = sudden cardiac death
ventricular tachycardia
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1229myectomy at the St. Antonius Hospital, Nieuwegein,
the Netherlands, between January 1981 and January
2010 were included. ASA was carried out from January
2000 onward. For patients to be selected for septum
reduction (either ASA or myectomy), they had to have
severe symptoms (New York Heart Association
[NYHA] functional class $3) despite optimal medical
therapy, in combination with a resting gradient of
30 mm Hg and/or a provocable gradient $50 mm Hg.
Patients with concomitant (sub)valvular disease, cor-
onary artery disease, or other conditions that war-
ranted surgery underwent myectomy. Patients who
were eligible for both options were informed about
the known risks and beneﬁts of both ASA and surgical
myectomy and were offered the choice between these
procedures. We performed a retrospective analysis of
all baseline characteristics and periprocedural com-
plications. Long-term survival and clinical outcome
were investigated using a questionnaire and hospital
records. The study conformed to principles deﬁned in
the Declaration of Helsinki. Local institutional review
board approval was obtained.
PROCEDURE. ASA was performed as described in
detail previously (10). In short, with the aid of a
ﬂexible coronary guidewire, a coronary balloon was
placed in the most proximal septal perforator branch.
Myocardial contrast echocardiography was used for
further guidance. Only when the region of contrast in
the septum was judged satisfactory and adjacent to
the area of septal contact of the anterior mitral valve
leaﬂet, 0.5 to 3 ml of concentrated ethanol was slowly
injected through the inﬂated balloon catheter. The
balloon was left inﬂated for 10 min to prevent retro-
grade spill of ethanol. Invasive gradients in the LVOT
were measured continuously during the procedure
using a 6-F pigtail catheter inserted in the left
ventricle. For testing of a provocable gradient, the
Valsalva maneuver and extrasystolic beats were used.
When the gradient in the LVOT remained $30 mm Hg
after the ﬁrst ablation (either at rest or after provo-
cation), the procedure was repeated in 1 or 2 more
accessible septal branches. During the procedure, all
patients received a temporary transvenous pace-
maker. If an atrioventricular block remained >48 h
after the procedure, a deﬁnitive pacemaker was
implanted.
Myectomy was performed as described previously
(11). Perioperative transesophageal echocardiography
and visual inspection by the surgeon were performed
to determine the extension of the myectomy and any
(sub)valvular abnormalities. When necessary, surgery
was combined with coronary artery bypass grafting
(CABG).FOLLOW-UP. The degree of LVOT obstruc-
tion before intervention was measured using
transthoracic echocardiography. Determina-
tion of the gradient directly after surgical
myectomy was performed intraoperatively
using transesophageal echocardiography.
The gradient post-ASA was determined inva-
sively immediately after the procedure. For
follow-up, the last available report of an
echocardiogram was used for determination
of left ventricular ejection fraction and the
gradient in the LVOT. A questionnaire was
sent to all patients still alive in December
2010. In this questionnaire, patients were
asked about their symptomatic status, NYHA
functional class status (1 to 4), chest pain, and syn-
cope. Clinical events (readmittance for heart failure,
a repeat intervention with ASA or surgical myec-
tomy, and appropriate implantable cardioverter-
deﬁbrillator [ICD] shocks) were captured any time
after the procedure using hospital records and
questionnaires. Inquiry by telephone was used to
complete data when necessary. Civil registries were
used to determine whether patients were still alive.
The cause of death was obtained from hospital and
general practitioner records.
STUDY ENDPOINTS. The primary endpoint was all-
cause mortality and was determined during a
maximal follow-up period of 11 years after both pro-
cedures. Secondary endpoints consisted of annual
cardiac death rate, NYHA functional class at late
follow-up, rehospitalization due to heart failure,
reintervention, cerebrovascular accident (CVA), and
myocardial infarction and were determined during
the entire follow-up period (average, 9.1 [inter-
quartile range (IQR): 3.3 to 13.5] years after myectomy
and 5.1 [IQR: 2.9 to 7.5] years after ASA). Cardiac
death consisted of death due to heart failure and or
sudden cardiac death (SCD). To prevent underesti-
mation of cardiac death, deaths of unknown cause
were also considered as cardiac death. Patients with
an ICD were investigated for appropriate ICD shocks.
Complications were considered periprocedural when
occurring during the intervention or in the ﬁrst 30
days after the intervention.
STATISTICAL ANALYSIS. Data are given as mean 
SD when normally distributed, as median and inter-
quartile range for skewed distributions, and as fre-
quencies and percentages for categorical variables.
The Student t test (2-paired) and Mann-Whitney U
test were used to compare variables between groups,
where appropriate. The Fisher exact test was used for
comparison of categorical variables. Cox proportional
VT =
TABLE 1
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Male
NYHA fun
Angina (C
Syncope
LVH >30
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Medical h
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1230hazard analysis was carried out for the ﬁrst occur-
rence of all-cause mortality. All baseline variables
listed in Table 1 were considered in the multivariate
models when a p value <0.1 was obtained on uni-
variate analysis. In a second analysis, type of treat-
ment (myectomy or ASA) was forced into the
multivariate model to evaluate the multivariate effect
on outcome. Due to the difference in follow-up
duration, cardiac mortality and clinical events were
compared on an annual basis. All-cause mortality
was also compared during a maximal follow-up
duration of 11 years after both procedures. All re-
ported probability values are 2 tailed, and a p value
<0.05 was considered statistically signiﬁcant. Statis-
tical analyses were performed using STATA version
11.0 (StataCorp, College Station, Texas).
RESULTS
A total of 161 patients underwent ASA and 102 pa-
tients underwent myectomy. Baseline characteristicsBaseline Characteristics
Parameter
Myectomy
(n ¼ 102)
ASA
(n ¼ 161) p Value
56  16 59  14 0.09
46 (47) 53 (85) 0.31
ctional class (I/II/III or IV), % 5/19/76 1/19/80 0.12
CS) 2.3  0.6 2.0  0.5 0.002
20 (20) 18 (29) 0.74
mm 5.9 (6) 5.6 (9) 0.999
ter monitoring 1 (1) 6 (10) 0.17
ker or calcium channel blocker 88 (90) 80 (129) 0.16
istory
s CVA 2.0 (2) 1.2 (2) 0.999
s AF 21 (21) 15 (24) 0.67
y artery disease 17 (17) 5 (8) 0.004
2.9 (3) 2.5 (4) 0.999
iate shock 1.0 (1) 0.6 (1) 0.999
ker 1.0 (1) 4.3 (7) 0.16
tory of SCD 11 (11) 9 (14) 0.66
tory of HCM 23 (23) 19 (31) 0.53
gram
hickness, mm 20 (17–24) 21 (19–24) 0.03
r wall thickness, mm 14  3 15  4 0.01
of MI 2.0  1.1 1.6  1.0 0.38
t baseline, mm Hg 50 (25–75) 32 (18–75) 0.088
t after provocation, mm Hg 95 (70–120) 101 (69–150) 0.31
intervention
y þ CABG 18 (18) — —
CI — 2.5 (4) —
ean  SD, % (n), or median (interquartile range) for skewed distributions.
ohol septal ablation; AF ¼ atrial ﬁbrillation; CABG ¼ coronary artery bypass grafting;
dian Cardiovascular Society; CVA ¼ cerebrovascular accident; HCM ¼ hypertrophic
athy; ICD ¼ implantable cardioverter-deﬁbrillator; LVH ¼ left ventricular hypertrophy;
rdial infarction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary
; SCD ¼ sudden cardiac death; VT ¼ ventricular tachycardia.of the 2 treatment groups are shown in Table 1.
Angina pectoris and coronary artery disease were
more common in patients who underwent myectomy.
Also, revascularization by combining CABG with
myectomy was more common than revascularization
by combining percutaneous coronary intervention
with ASA. Septal and posterior wall diameters were
slightly larger in the ASA patients. Other baseline
characteristics were comparable.
PERIPROCEDURAL COMPLICATIONS. Periprocedural
severe complications (death, CVA, and ventricular
tachycardia (VT)/ventricular ﬁbrillation) after ASA
and myectomy were not signiﬁcantly different
(Table 2). One patient in the ASA group died because
of spill of alcohol, and a second patient died because
of tamponade caused by a pacemaker lead perfora-
tion. Two patients died of refractory cardiogenic
shock after myectomy. In the ﬁrst patient, no cause of
the cardiogenic shock was identiﬁed; in the second
patient, the cause was right ventricular infarction.
Two other patients who underwent myectomy had a
disabling CVA. A repeat thoracotomy was necessary
in 11 patients, in 7 because of excessive bleeding,
2 underwent an additional myectomy because of a
signiﬁcant residual gradient, 1 had an aneurysm of
the aortic sinus needing repair, and in 1 a ventricular
septal rupture occurred that was repaired with a
patch. After ASA, closure of a ventricular septal
rupture was also performed but at a later stage, and
this was combined with a myectomy. All repeat
thoracotomies were performed successfully and were
not associated with a worse long-term outcome.
Other periprocedural complications were comparable
between ASA and myectomy (Table 2). The total per-
iprocedural complication frequency was lower in the
ASA group compared with the myectomy group (14%
[22 of 161] vs. 28% [29 of 102], p ¼ 0.004). When
comparing ASA and myectomy in the same time
period of 2000 to 2010, 77% (161 of 209) of patients
underwent ASA. In this time period, ASA patients also
had a lower periprocedural complication frequency
than the myectomy patients (14% [22 of 161] vs. 38 %
[18 of 48], p < 0.001). Patients after ASA also had a
lower complication frequency compared with pa-
tients after myectomy without CABG (14% [22 of 161]
vs. 29% [24 of 84], p ¼ 0.006). Complication fre-
quency of patients undergoing surgical myectomy
with CABG was comparable to that of patients un-
dergoing myectomy without CABG (28% [5 of 18] vs.
29% [24 of 84], p ¼ 1.0).
SURVIVAL AND APPROPRIATE ICD SHOCKS. Follow-up
was completed in 99% (261 of 263) of the study pop-
ulation. Two patients were lost to follow-up due to a
TABLE 3 Clinical Outcome
Myectomy
(n ¼ 102)
ASA
(n ¼ 159) p Value
Follow-up duration, yrs 9.1 (3.3–13.5) 5.1 (2.9–7.5) <0.0001
All-cause death, annual 2.2 (21) 1.5 (13) 0.25
Cardiac death, annual 1.4 (13) 0.7 (6) 0.15
Noncardiac death, annual 0.8 (8) 0.8 (7) 0.91
NYHA functional class
(I/II/III or IV), %
52/30/18 53/31/16 0.89
Angina status (CCS) 0.5  0.9 0.7  1.0 0.14
Syncope 2.0 (2) 8.2 (13) 0.053
Rehospitalization for heart
failure, annual
0.6 (6) 0.3 (3) 0.40
MI, annual 0.2 (2) 0.1 (1) 0.66
CVA, annual 0.5 (5) 0.3 (3) 0.57
ICD implantation 1 (1) 3 (5) 0.41
Appropriate ICD shock (0) (0) -
Reintervention 1 (1) 6.3 (10) 0.055
Repeat ASA - 3.8 (6) 0.08
Repeat myectomy 1 (1) 2.5 (4) 0.65
Post-procedural gradient,
mm Hg
12 (8–20) 10 (0–20) < 0.001
Echocardiogram
(late follow-up)
Gradient baseline, mm Hg 9 (4–10) 10 (7–19) 0.003
Gradient after provocation,
mm Hg
10 (7–13) 19 (10–42) < 0.001
Ejection fraction % 61  11 63  8 0.26
Values are median (interquartile range) for skewed distributions, an annual per-
centage (total numbers during total follow-up period), or mean  SD.
Abbreviations as in Table 1.
TABLE 2 Periprocedural Complications (30 Days)
Myectomy
(n ¼ 102)
ASA
(n ¼ 161) p Value
Periprocedural death 2.0 (2) 1.2 (2) 0.56
Ventricular ﬁbrillation/sustained VT 0 2.5 (4) 0.16
CVA 2 (2) 0 0.15
Dissection LAD 0 0.6 (1) 1.0
Pneumothorax 2 (2) 0.6 (1) 0.56
Mediastinitis 2 (2) 0 0.15
Pacemaker infection 0 1.2 (2) 0.52
Pacemaker implantation 9 (9) 7 (11) 0.64
Tamponade 8.8 (9) 1.2 (2) 0.004
Urgent repeat thoracotomy 11.4 (11) 0 < 0.001
All complications (1 per patient) 28 (29) 14 (22) 0.004
Length of hospital stay, days 9 (6–12) 5 (4–6) <0.001
Values are % (number) and median (interquartile range) for skewed distributions.
LAD ¼ left anterior descending artery; other abbreviations as in Table 1.
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1231foreign address. During the maximal follow-up
duration of 11 years, all-cause mortality after ASA
and myectomy was comparable (Table 3, Figure 1),
and after multivariate analysis, only age at baseline
was an independent predictor (Table 4). After type of
procedure was forced into a second multivariate
analysis, ASA versus myectomy was also not associ-
ated with death (hazard ratio: 1.20 [95% conﬁdence
interval: 0.49 to 2.94], p ¼ 0.69). The median follow-
up duration was 9.1 years (IQR: 3.3 to 13.5 years) after
myectomy and 5.1 years (IQR: 2.9 to 7.5 years) after
ASA. After myectomy, 2 deaths were due to heart
failure, 2 patients had SCD, and in 9 patients, the
cause of death was unknown. After ASA, 3 deaths
were due to heart failure, and in 3 patients, the cause
of death could not be determined. Even when the
deaths of unknown causes were considered to be
cardiac deaths, the annual occurrence of cardiac
death after ASA and myectomy was comparable
(Table 3). In total, 7 ICDs were implanted before the
procedure (myectomy, n ¼ 3; ASA, n ¼ 4), and a total
of 6 ICDs were implanted after the procedure (myec-
tomy, n ¼ 1; ASA, n ¼ 5) (Tables 1 and 2). No appro-
priate ICD shocks were observed during the entire
follow-up period in any of the patients with ICDs.
TREATMENT EFFECT. Questionnaires for symptom-
atic status were completed in 96% (220 of 229) of
patients still alive at follow-up. No differences were
found between myectomy and ASA patients for
symptomatic status, rehospitalization for heart fail-
ure, CVA, and myocardial infarction at follow-up
(Table 3). Echocardiograms at late follow-up were
retrieved for 92% (241 of 263) of patients with an
average interval after the procedure of 3.9  4.7 years.Baseline and provoked gradients in the LVOT at late
follow-up were higher for patients after ASA (Table 3).
A total of 10 reinterventions because of both a sig-
niﬁcant residual/recurrent gradient and symptoms
were performed after ASA; 6 by means of ASA and 4
with surgical myectomy, whereas a second procedure
(i.e., ASA) was performed in the myectomy group
(6.3% vs. 1.0%, p ¼ 0.055) (Table 3).
DISCUSSION
The main ﬁnding of the study is that long-term sur-
vival in our single-center study was comparable after
ASA and myectomy. In addition, we found that long-
term symptomatic improvement after both pro-
cedures was comparable as well as the occurrence of
cardiac death, CVA, myocardial infarction, and reho-
spitalization for heart failure. However, ASA was
associated with a lower frequency of periprocedural
complications and a shorter duration of hospital stay
compared with myectomy.
PERIPROCEDURAL COMPLICATIONS. Severe periproce-
dural complications (death, CVA, and VT/ventricular
FIGURE 1 Survival After ASA Versus Myectomy
Cumulative survival after alcohol septal ablation (ASA) and myectomy using Cox propor-
tional hazard analysis.
TABLE 4 Predictors
Parameter
ASA vs. myectomy
Age (per 5 yrs)
Female
NYHA functional class
Previous AF
Coronary artery disease
Baseline septal thicknes
Maximal follow-up time fo
CI ¼ conﬁdence interval
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1232ﬁbrillation) were comparable between both treat-
ments (Table 2) and largely comparable to previous
studies (7,12,13). Regarding the need for pacemaker
implantation, the results after myectomy and ASA
were also comparable, which is somewhat at variance
with data reported in the literature, including in
meta-analyses, generally showing a greater need for
pacemaker implantation after ASA (4,5). Importantly,
in these meta-analyses, age at baseline was higher for
ASA, which may have confounded the association
between ASA patients and the need for pacemaker
implantation, whereas in the present study, age at
baseline was comparable for ASA and myectomy.
Another explanation for the comparable rate of
pacemaker implantation in the present study may beof All-Cause Mortality
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
0.84 (0.38–1.84) 0.66
1.42 (1.18–1.71) <0.001 1.34 (1.08–1.65) 0.007
1.99 (0.90–4.41) 0.090 1.25 (0.48–3.23) 0.64
(III/IV vs. I/II) 1.81 (0.62–2.28) 0.279
0.89 (0.30–2.58) 0.83
2.96 (1.11–7.90) 0.030 2.56 (0.92–7.14) 0.072
s, mm 1.03 (0.91–1.18) 0.63
r both groups is 11 years.
; HR ¼ hazard ratio; other abbreviations as in Table 1.the periprocedural use of myocardial contrast echo-
cardiography or the judicious use of alcohol in the
present study (14,15).
The total frequency of periprocedural complica-
tions in the present study was, however, lower for
patients undergoing ASA compared with myectomy,
and this has not been reported previously. Also after
correction for the time period and after exclusion of
myectomy combined with CABG, the frequency of
complications remained lower after ASA. The differ-
ence in complication frequency was mainly due to a
need for repeat thoracotomy after myectomy (because
of bleeding, tamponade, repair of an aneurysm of the
aortic sinus, and the need for a second myectomy).
These complications and the longer hospital stay after
myectomy reﬂect the more invasive nature of myec-
tomy. Nevertheless, all periprocedural complications
were treated successfully and were not associated
with a worse long-term outcome.
LONG-TERM OUTCOME. One of the feared long-term
complications after ASA is the possible predisposition
for ventricular arrhythmia after the induction of a
septal infarction (1). In 1 single-center study, a higher
rate of ICD shocks and SCD was found after ASA
compared with myectomy (9). In the present study,
other recent studies, and a meta-analysis, the oc-
currence of SCD and appropriate ICD shocks was
comparable and uncommon both after ASA and
myectomy (4–8). However, it should be stressed that
post-septal reduction hypertrophic cardiomyopathy
patients at high risk of SCD (irrespective of the pro-
cedure) should nonetheless be considered for ICD
implantation (16).
Regarding the treatment effect, long-term symp-
tomatic results determined with a questionnaire
were comparable with a sustained beneﬁt after both
interventions at long-term follow-up, which is
comparable to a previous single-center study (7).
We also did not ﬁnd any difference in cardiovas-
cular events during long-term follow-up. A trend
was seen for more syncope after ASA, but this did
not reach statistical signiﬁcance. Post-procedural
gradients after ASA and myectomy were measured
under different circumstances using different tech-
niques (invasive vs. transesophageal echocardio-
graphy) and therefore cannot be compared. At
long-term follow-up, echocardiographic gradients
were slightly higher for ASA patients compared with
myectomy patients in the present study. The num-
ber of reinterventions after ASA in the present
study was low (6%) compared with 8% to 9% in
previous studies (7,17). In the myectomy group,
only 1 reintervention was performed (1%). In
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12332 patients, the myectomy procedure was immedi-
ately repeated after evaluation with intraoperative
transesophageal echocardiography requiring a sec-
ond pump run. They were counted as complications
and not as a reintervention.
STUDY LIMITATIONS. Like all previous studies
comparing ASA and myectomy, this study was a
nonrandomized, observational study. However, with
the exception of concomitant coronary artery disease
and a slight difference in the degree of left ventric-
ular hypertrophy, all clinical characteristics in the 2
treatment groups were comparable. In particular, the
average age was comparable in the 2 groups, which
suggests that selection bias did not play a major role.
The low prevalence of VT on Holter monitoring in
myectomy patients was possibly related to missing
Holter monitoring reports in these patients. Another
potential limitation is the fact that myectomy was
performed during a longer time period than ASA.
ASA patients were therefore treated in a more mod-
ern era, which could have inﬂuenced our results.
However, after statistical correction, these factors
did not translate to a difference in survival between
both treatment groups. Also, the difference in peri-
procedural complications frequency between ASA
and myectomy remained after correction for the
same time period. A strength of the study is the long
follow-up and the completeness of the data. An
extensive search of all hospital records and opera-
tion reports was performed and completed for com-
plications in all patients. Questionnaires and, when
necessary, consulting by telephone were used to
obtain a more objective result of symptomatic
status of the patient at late-term follow-up. Finally,unlike many other studies, a strength of the study
is the fact that both periprocedural complications
and long-term outcome were analyzed in a single
study.
CONCLUSIONS
This study adds to the increasing body of evidence
(4–8) that long-term survival, clinical outcome in
terms of symptomatic status, risk of heart failure, and
arrhythmic events after ASA is good and comparable to
that of myectomy. Due to the comprehensiveness of
the present study, in addition to advantages, some
disadvantages of a more invasive surgical versus a
percutaneous procedure have become clear. After
ASA, the periprocedural complication frequency was
lower and duration of hospital stay was shorter,
reﬂecting its less invasive nature compared with
myectomy. On the other hand, gradients after myec-
tomy are lower at late follow-up, which could favor
myectomy. Furthermore, some conditions warrant
a surgical approach such as coronary septal anatomy
unsuitable for ASA (18), (sub)valvular abnormali-
ties, or multivessel coronary artery disease. Taken
together, patients should be evaluated on an individ-
ual basis by a multidisciplinary team of cardiologists
and surgeons. When both procedures are feasible,
after providing adequate information, preference of
the patient should be part of the equation to determine
the best treatment option.
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